Chronic angiotensin II receptor blockade reduces (intra) renal vascular resistance in patients with type 2 diabetes

被引:85
作者
Fliser, D
Wagner, KK
Loos, A
Tsikas, D
Haller, H
机构
[1] Hannover Med Sch, Dept Internal Med, D-30625 Hannover, Germany
[2] Hannover Med Sch, Inst Clin Pharmacol, D-30625 Hannover, Germany
来源
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2005年 / 16卷 / 04期
关键词
D O I
10.1681/ASN.2004100852
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Increased (intra)renal activity of the renin-angiotensin system may cause a persistent increase in renovascular resistance and intraglomerular pressure in patients with diabetes, thus contributing to the development of diabetic renal damage. The effect of chronic angiotensin II subtype I receptor blockade on (intra)renal hemodynamics in patients with type 2 diabetes was examined in a double-blind parallel group study. Patients were treated with 40 mg of olmesartan (n = 19) or placebo (n = 16), and renal hemodynamics were assessed before and after 12 wk of treatment using inulin and para-aminohippurate clearance techniques. Olmesartan significantly reduced 24-h ambulatory systolic and diastolic BP (both P < 0.05). In parallel, effective renal plasma flow increased significantly from 602 +/- 76 to 628 +/- 87 ml/min per 1.73 m(2), whereas filtration fraction and renovascular resistance decreased significantly (all P < 0.05). With placebo treatment, effective renal plasma flow decreased and filtration fraction increased significantly (both P < 0.05). GFR was not affected by both treatments. Active plasma renin concentration increased considerably (P < 0.05) with olmesartan therapy but remained unchanged with placebo treatment. Nitric oxide metabolism (plasma nitrate and nitrite) and asymmetric dimethylarginine blood levels were not affected by olmesartan and placebo therapy. In contrast, plasma 8-isoprostane 15(S)-8-iso-prostaglandin F-2a concentration, a biochemical marker of oxidative stress, decreased significantly (P < 0.05) with olmesartan treatment. Chronic angiotensin II subtype I receptor blockade decreases (intra)renal vascular resistance and increases renal perfusion despite significant BP reduction. In addition, it significantly reduces oxidative stress. These effects of angiotensin II receptor antagonists may contribute to their beneficial long-term renal effects in patients with type 2 diabetes.
引用
收藏
页码:1135 / 1140
页数:6
相关论文
共 37 条
[31]   Application of gas chromatography-mass spectrometry for analysis of isoprostanes:: Their role in cardiovascular disease [J].
Schwedhelm, E ;
Böger, RH .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2003, 41 (12) :1552-1561
[32]   Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists [J].
Taal, MW ;
Brenner, BM .
KIDNEY INTERNATIONAL, 2000, 57 (05) :1803-1817
[33]   Quantitative determination of circulating and urinary asymmetric dimethylarginine (ADMA) in humans by gas chromatography-tandem mass spectrometry as methyl ester tri(N-pentafluoropropionyl) derivative [J].
Tsikas, D ;
Schubert, B ;
Gutzki, FM ;
Sandmann, J ;
Frölich, JC .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2003, 798 (01) :87-99
[34]   Divergence in urinary 8-iso-PGF2x (iPF2x-III 15-F2t-IsoP) levels from gas chromatography tandem mass spectrometry quantification after thin-layer chromatography and immunoaffinity column chromatography reveals heterogeneity of 8-iso-PGF2x -: Possible methodological, mechanistic and clinical implications [J].
Tsikas, D ;
Schwedhelm, E ;
Suchy, MT ;
Niemann, J ;
Gutzki, FM ;
Erpenbeck, VJ ;
Hohfeld, JM ;
Surdacki, A ;
Frölich, JC .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2003, 794 (02) :237-255
[35]   Simultaneous derivatization and quantification of the nitric oxide metabolites nitrite and nitrate in biological fluids by gas chromatography/mass spectrometry [J].
Tsikas, D .
ANALYTICAL CHEMISTRY, 2000, 72 (17) :4064-4072
[36]   Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction [J].
Wassmann, S ;
Hilgers, S ;
Laufs, U ;
Böhm, M ;
Nickenig, G .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (07) :1208-1212
[37]   Diabetic nephropathy in type 2 diabetes prevention and patient management [J].
Wolf, G ;
Ritz, E .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (05) :1396-1405